Integrated products and personalization drive biotic innovation – insights from the Exclusive Growth Asia Summit

[ad_1]

This is according to Evan Hayes, Managing Director, Asia Pacific, Factors Group, in a public address at the recent Growth Asia Summit 2022 in Marina Bay Sands, Singapore.

“Probiotics continues to be one of the newest health categories and continues to grow from consumer awareness to product innovation, research, IP and more. The industry still has many hurdles and hurdles to overcome, but even now we are seeing the category. has evolved beyond the category of gut health, where it is usually originally thought of as “Hayes said.

“In the last 10 years, research has evolved in many different directions, and we’ve gone from next-generation probiotics to postbiotics, synbiotics, and more. we see the emergence of many different categories of biotics..

“It’s become increasingly clear that looking at just probiotics means we’re not using the whole toolkit in the space, which includes not only prebiotics and probiotics, but also other adjacent fields.”.

Some areas noted by Hayes include synbiotics – combinations of prebiotics and probiotics that either provide individual benefits from each, or a new independent benefit from the combination; postbiotics are metabolites produced by microorganisms that can enhance new probiotic functions; as well as other types of strategic combinations that enhance health effects.

“Strategic combination options, such as scobiotics, which are syntrophic mixed cultures of bacteria, fungi and yeasts, tailored for different health effects, are a very promising area of development in this sector,”he said.

He also highlighted the company’s range of Scobiotics.

“Scobiotics can act by providing direct effects such as colonizing the gut, producing necessary inhibitory compounds such as certain short-chain fatty acids, releasing beneficial microbes and substrates to enhance immune responses; or inhibiting the attachment of pathogens, strengthening the intestinal barrier, reducing intestinal inflammation, etc. through indirect measures such as.

“For example, we’ve seen products like Biome Clear, which is a scobiotic to support detoxification, help reverse the effects of dysbiosis, address issues such as overproduction of surface-level proteins to remove heavy metals or polysaccharides that reduce elimination. process..

Another expected future direction of the sector is probiotics/postbiotics/synbiotics/etc. including tailored, personalized solutions. designed and developed based on the individual needs of customers.

“We see probiotics becoming more and more relevant to personalization,”Hayes said.

“There will be some sort of diagnostic to see what a good microbiome looks like for the consumer, and then brands will work backwards to fill in the gaps with the biotics to maximize the desired and dialed in. reduce the unwanted..

“So, yes, the future is based on the desired applications and uses many things other than bacteria to satisfy the desired functions and benefits.”.

As opposed to beneficial bacteria in general.

Looking more closely at the realm beyond bacteria, Hayes also pointed to yeast, which is thought to provide benefits to the microbiome in another way, as an area of increasing interest in the space.

“More and more firms are looking at yeast as a good potential addition to their portfolio,”he said.

“There has been a real surge of interest in this area because it can be a source of beneficial compounds for the body, especially the gut.”.

As for other types of targeted solutions, there is also interest in considering site-specific implementations, such as small intestinal versus colonic formulations, as the former have fewer bacteria and are more prone to interference than the latter. may be more suitable for direct solutions, while colonic intervention may be better with the use of prebiotics to effect long-term changes.

[ad_2]

Source link